Cagrilintide + Semaglutide
Peptide Stack · Combination ConceptComplementary amylin + GLP-1 appetite/satiety/weight-regulation signaling
What Is This Combination?
ERP catalog context: Cagrilintide 5 mg + Semaglutide 5 mg -- total 10 mg
The only initial Combination Concept page with direct human exact-combination evidence: distinct amylin (Cagrilintide) and GLP-1 (Semaglutide) pathways studied together in a clinical development program -- though the ERP research vial is not the same product as the studied pharmaceutical formulation.
The Concept
Distinct amylin and GLP-1 pathways both affect satiety, appetite, and energy intake through different signaling systems. Unlike the other seven pages in this set, this pairing has been directly studied together in human trials -- including Enebo et al.'s 2021 concomitant-administration work, an earlier Lau et al. 2021 cagrilintide-monotherapy Phase 2 trial, a Frias et al. 2023 trial in adults with type 2 diabetes, and the REDEFINE Phase 3 program (REDEFINE 1, REDEFINE 2, and the REDEFINE 3 cardiovascular-outcomes trial).
Meet the Components
Cagrilintide
5 mgamylin-receptor satiety signaling arm
Cagrilintide is a long-acting amylin-receptor agonist studied for effects on satiety and food intake through a pathway distinct from GLP-1-receptor agonism.
See the standalone Cagrilintide page for its full evidence summary.
Human evidence, studied as part of an investigational combination program
View Cagrilintideresearch profile →Semaglutide
5 mgGLP-1-receptor appetite/satiety signaling arm
Semaglutide is a GLP-1-receptor agonist studied extensively for effects on appetite, satiety, and body weight through a pathway distinct from amylin-receptor agonism.
See the standalone Semaglutide page for its full evidence summary.
Extensive independent human evidence
View Semaglutideresearch profile →How the Roles Fit Together
What the Combination Is Intended to Address
Evidence-Supported Conceptual Domains
- overweight/obesity clinical research
- satiety and appetite regulation
- body-weight regulation
- cardiometabolic research outcomes
Community-Use Themes
The themes below are editorial summaries of commonly discussed community-use patterns. They are not controlled clinical evidence, systematically sourced community data, or established benefits.
- fullness and satiety experience(editorial-summary)
- appetite suppression discussions(editorial-summary)
- gastrointestinal tolerability discussions(editorial-summary)
- difficulty maintaining food or protein intake(editorial-summary)
Concerns & Evidence Gaps
Safety Consideration
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are commonly reported with both GLP-1 and amylin-receptor agonists and may be more prominent when combined.Safety Consideration
Reduced food intake from combined appetite suppression carries its own nutritional-adequacy considerations.Safety Consideration
Tolerability of each component individually should be separately understood before combining them.Safety Consideration
A fixed-ratio research vial limits independent titration of each component, unlike the studied clinical program's dosing schedule.Safety Consideration
The ERP research-vial product's equivalence to the exact studied pharmaceutical formulation cannot be assumed.
Why Separate Components May Sometimes Be Preferable
Presented as a scientific/practical tradeoff, not a recommendation.
Favoring Separate Administration
- The studied clinical program titrates each component on its own schedule; a fixed-ratio vial cannot replicate that independent titration.
- Separate administration makes it possible to isolate which component is responsible for a given tolerability issue.
- Product-equivalence uncertainty applies specifically to a fixed combined vial, not to sourcing each component individually against its own standalone evidence.
Favoring the Fixed-Ratio Blend
- A single combined vial is more convenient to source and administer than two separate components on two schedules.
Convenience is not evidence of biological superiority.
Evidence Boundary
The components of this combination have been investigated individually to varying degrees. Evidence for an individual component does not automatically establish the safety, efficacy, compatibility, or synergy of the exact combination. Where direct combination studies exist, MitoCore identifies that explicitly. Where they do not, the page describes the biological rationale for the combination rather than presenting the stack itself as a validated therapeutic intervention.
Exact-combination status: Direct human evidence exists for the co-administration of cagrilintide and semaglutide. Novo Nordisk's clinical development program -- including Enebo et al.'s 2021 Phase 1b concomitant-administration study and the REDEFINE 1, REDEFINE 2, and REDEFINE 3 Phase 3 trials (REDEFINE 1 alone enrolled 3,417 adults with overweight or obesity) -- has directly studied this combination in humans, unlike the other seven pages in this set.
Limitations: This direct clinical evidence was generated using Novo Nordisk's specific investigational pharmaceutical formulation, dosing regimen, and titration schedule. An ERP research-vial product at 5 mg + 5 mg is not automatically equivalent in identity, purity, formulation, manufacturing, dose delivery, or regulatory status to that studied product; this page's evidence summary describes what the clinical program studied, not a claim about the ERP vial itself.
Component evidence: Both components also carry extensive independent evidence bases of their own -- see the standalone Cagrilintide and Semaglutide pages for each component's full evidence summary.
Explore the Components
Each component's full evidence base lives on its own standalone research profile.
Cagrilintide
Cagrilintide is a long-acting amylin analog studied for weight management, both alone and combined with semaglutide (as CagriSema). It mimics the satiety hormone amylin to reduce food intake, and has shown meaningful weight loss in completed Phase 2 and Phase 3 human trials.
View research profile →Semaglutide
Semaglutide is a GLP-1 receptor agonist FDA-approved under three brand names (Ozempic, Wegovy, Rybelsus) for type 2 diabetes and/or chronic weight management, with the largest published trial program of any current obesity medication.
View research profile →Disclaimer
See the anecdotal notice above for community-discussion context.
This page does not establish combination efficacy, safety, or compatibility beyond what is explicitly cited above. Always review each component's own standalone research profile for its full evidence base.